Evidence map›Paper›PMID 41479559›Full record

ReviewInternational journal of nanomedicine2025

Nanocomposites to Overcoming Sorafenib Resistance in Hepatocellular Carcinoma Therapy.

Jie Liu, Shizhao Zhou, Yingying Wei, Jinglei Du, Fan Jia, Wenhui Dong, Yangyi Cao, Zhenyang Shi, Hongkai Mu, Lin Chen and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jie Liu *Medical Imaging Department, Shanxi Medical University, Taiyuan, Shanxi, 030001, People's Republic of China.
Shizhao Zhou *Medical Imaging Department, Shanxi Medical University, Taiyuan, Shanxi, 030001, People's Republic of China.
Yingying WeiDepartment of Interventional Therapy, Shanxi Province Cancer Hospital, Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences, Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, Shanxi, 030013, People's Republic of China.
Jinglei DuDepartment of Interventional Therapy, Shanxi Province Cancer Hospital, Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences, Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, Shanxi, 030013, People's Republic of China.ORCID 0000-0003-1992-1363
Fan JiaDepartment of Oncology and Vascular Intervention, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, 030001, People's Republic of China.
Wenhui DongMedical Imaging Department, Shanxi Medical University, Taiyuan, Shanxi, 030001, People's Republic of China.
Yangyi CaoAcademy of Medical Sciences, Shanxi Medical University, Taiyuan, Shanxi, 030001, People's Republic of China.
Zhenyang ShiMedical Imaging Department, Shanxi Medical University, Taiyuan, Shanxi, 030001, People's Republic of China.
Hongkai MuMedical Imaging Department, Shanxi Medical University, Taiyuan, Shanxi, 030001, People's Republic of China.
Lin ChenKey Laboratory of Interface Science and Engineering in Advanced Materials, Ministry of Education, Taiyuan University of Technology, Taiyuan, Shanxi, 030024, People's Republic of China.
Shiping YuDepartment of Interventional Therapy, Shanxi Province Cancer Hospital, Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences, Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, Shanxi, 030013, People's Republic of China.ORCID 0000-0002-1783-1674

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The emergence of drug resistance is the major obstacle to the clinical application of sorafenib (SOR), which often leads to disease progression, recurrence, and even death in hepatocellular carcinoma (HCC) patients. Nanocomposite-mediated drug delivery enhances targeting precision and therapeutic utilization efficiency. Nanocomposites constructed by nanoparticles (NPs) and various therapeutic components have emerged as effective approaches to enhance HCC therapeutic efficacy. Designing based on the mechanisms underlying SOR resistance, specially engineered nanocomposites can be designed to overcome SOR resistance. This review aims to highlight the advantages of nanocomposites in overcoming HCC SOR resistance. First, the various SOR resistance mechanisms that have been identified so far are briefly outlined. Second, the construction methods and characteristics of nanocomposites designed to overcome SOR resistance are summarized and categorized according to different types of NPs. Subsequently, the roles and therapeutic effects of nanocomposites in SOR-resistant HCC are analyzed, primarily including remodeling the tumor microenvironment (TME), restoring normal epigenetic regulation, improving drug metabolism, and inhibiting abnormally activated signaling molecules and pathways. Finally, the advantages and disadvantages of nanocomposites used to reverse drug resistance are discussed, and their development direction in future research is prospected, which provide new approaches for developing advanced nanocomposites to overcome SOR resistance.

Indexed as

Antineoplastic AgentsCarcinoma, HepatocellularDrug Resistance, NeoplasmLiver NeoplasmsNanocompositesSorafenibAnimalsDrug Delivery SystemsHumansTumor MicroenvironmentAntineoplastic AgentsSorafenibcombination therapiesdrug deliverydrug resistancehepatocellular carcinomananocompositesnanomedicinenanoparticlessorafenib

Identifiers

PMID41479559
PMCPMC12753898

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.